文献速递肿瘤 PET/CT核素与放射性配体治疗

177Lu-PSMA治疗前定义PSMA阳性的阈值:转移性前列腺癌中[68Ga]Ga-PSMA-11与[18F]F-DCFPyL的比较

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer.
PubMed 文献 · EJNMMI Res · 2023-09-20

本研究比较了[68Ga]Ga-PSMA-11 PET与[18F]F-DCFPyL PET在转移性前列腺癌患者中肿瘤-肝脏比值和肿瘤-纵隔比值的可比性,以探讨在177Lu-PSMA治疗前定义PSMA阳性的阈值。结果显示两种示踪剂在肿瘤-肝脏比值和肿瘤-纵隔比值上无差异,但[18F]F-DCFPyL在对比度-噪声比上显著更优。结论认为基于肝脏背景的半定量评估,[18F]F-DCFPyL肿瘤摄取高于肝脏背景与[68Ga]Ga-PSMA-11同样适用于定义PSMA阳性。

要点

  • [68Ga]Ga-PSMA-11与[18F]F-DCFPyL PET的肿瘤-肝脏比值和肿瘤-纵隔比值无差异。
  • [18F]F-DCFPyL PET的对比度-噪声比显著优于[68Ga]Ga-PSMA-11 PET。
  • 基于肝脏背景的半定量评估,[18F]F-DCFPyL肿瘤摄取高于肝脏背景可同样用于定义PSMA阳性。

核心结论

  • [18F]F-DCFPyL PET与[68Ga]Ga-PSMA-11 PET提供可比的肿瘤-肝脏比值和肿瘤-纵隔比值。
  • 基于肝脏背景的半定量评估,[18F]F-DCFPyL肿瘤摄取高于肝脏背景与[68Ga]Ga-PSMA-11同样适用于定义PSMA阳性,例如在177Lu标记PSMA配体放射配体治疗前。
  • 数据提示[18F]F-DCFPyL在病灶可检测性方面有倾向性优势。

研究设计与样本

  • 分析采用[18F]F-DCFPyL PET与[68Ga]Ga-PSMA-11 PET确定的肿瘤-背景比值是否具有可比性。

主要发现

  • [68Ga]Ga-PSMA-11 PET与[18F]F-DCFPyL PET在肿瘤-肝脏比值或肿瘤-纵隔比值上未观察到差异。
  • 对比度-噪声比方面观察到显著差异,表明[18F]F-DCFPyL PET图像质量更好。

临床怎么用

  • 作者认为,基于肝脏背景的半定量评估,[18F]F-DCFPyL肿瘤摄取高于肝脏背景与[68Ga]Ga-PSMA-11同样适用于定义PSMA阳性,例如在177Lu标记PSMA配体放射配体治疗前。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA) ligands in metastatic prostate cancer. Theranostics require appropriate patients to be identified by positron emission tomography (PET) prior to radionuclide therapy, usually employing [68Ga]Ga-PSMA-11. Alternatively, several 18F-labelled PSMA-PET tracers are available and may increasingly replace 68Ga-labelled compounds, with respect to their image quality, availability and other practical advantages. However, alternative tracers may differ in uptake behaviour, and their comparability with regard to patient selection for [177Lu]Lu-PSMA therapy has not yet been established. Here, we analysed whether tumour-to-background ratios determined by PET using the 18F-labelled PSMA-specific radiopharmaceutical [18F]F-DCFPyL were comparable to those determined by PET using [68Ga]Ga-PSMA-11. RESULTS: No differences could be observed between [68Ga]Ga-PSMA-11-PET and [18F]F-DCFPyL-PET regarding tumour-to-liver ratios or tumour-to-mediastinum ratios (e. g. tumour-to-liver ratios using maximum SUV of the tumour lesion for ultra-high definition reconstructed PET images with a median of 2.5 (0.6-9.0) on [68Ga]Ga-PSMA-11-PET vs. 2,0 (0.6-11.4) on [18F]F-DCFPyL-PET). However, significant differences were observed in terms of contrast-to-noise ratios, thereby demonstrating the better image quality obtained with [18F]F-DCFPyL-PET. CONCLUSIONS: Our data showed that [18F]F-DCFPyl-PET and [68Ga]Ga-PSMA-11-PET provide comparable tumour-to-liver and tumour-to-mediastinum ratios. Therefore, a tumour uptake of [18F]F-DCFPyL above the liver background, like using [68Ga]Ga-PSMA-11, can be considered as equally suitable for defining PSMA-positivity by a semiquantitative assessment based on the liver background, e. g. prior to radioligand therapy with 177Lu-labelled PSMA ligands. In addition, our data suggest a tending advantage of [18F]F-DCFPyL in terms of lesion detectability.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Heilinger J, Weindler J, Roth KS, et al. Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer. EJNMMI Res. 2023. PMID: 37731097. doi:10.1186/s13550-023-01033-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。